An apolipoprotein B100 mimotope prevents obesity in mice

Hyo Joon Kim, Hee Jong Lee, Jung Soon Choi, Jemin Han, Ji Young Kim, Hyun Kyun Na, Hae Jung Joung, Young Sik Kim, Bert Binas

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    Although apolipoprotein B100 (ApoB100) plays a key role in peripheral fat deposition, it is not considered a suitable therapeutic target in obesity. In the present study we describe a novel ApoB100 mimotope, peptide pB1, and the use of pB1-based vaccine-like formulations (BVFs) against high-fat diet (HFD)-induced obesity. In HFD- compared with chow-fed adolescent mice, BVFs reduced the 3-month body-weight gains attributable to increased dietary fat by 44-65 %, and prevented mesenteric fat accumulation and liver steatosis. The body-weight reductions paralleled the titres of pB1-reactive immunoglobulin G (IgG) antibodies, and pB1-reactive antibodies specifically recognized native ApoB100 and a synthetic peptide from the C-terminal half of ApoB100. In cultured 3T3L1 adipocytes, anti-pB1 antibodies increased lipolysis and inhibited low-density lipoprotein (LDL) uptake. In cultured RAW 264.7 macrophages, the same antibodies enhanced LDL uptake (without causing foam cell formation). These findings make ApoB100 a promising target for an immunization strategy against HFD-induced obesity.

    Original languageEnglish
    Pages (from-to)105-116
    Number of pages12
    JournalClinical Science
    Volume130
    Issue number2
    DOIs
    Publication statusPublished - 2016

    Bibliographical note

    Publisher Copyright:
    © 2016 Authors.

    Keywords

    • ApoB100
    • High-fat-diet-induced obesity
    • Humoral immunity
    • Mimotope

    ASJC Scopus subject areas

    • General Medicine

    Fingerprint

    Dive into the research topics of 'An apolipoprotein B100 mimotope prevents obesity in mice'. Together they form a unique fingerprint.

    Cite this